NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4^th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18^th, at 2:30 pm ET.